1. Home
  2. KRYS vs KAI Comparison

KRYS vs KAI Comparison

Compare KRYS & KAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • KAI
  • Stock Information
  • Founded
  • KRYS 2015
  • KAI 1991
  • Country
  • KRYS United States
  • KAI United States
  • Employees
  • KRYS N/A
  • KAI N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • KAI Industrial Machinery/Components
  • Sector
  • KRYS Health Care
  • KAI Industrials
  • Exchange
  • KRYS Nasdaq
  • KAI Nasdaq
  • Market Cap
  • KRYS 4.3B
  • KAI 3.8B
  • IPO Year
  • KRYS 2017
  • KAI N/A
  • Fundamental
  • Price
  • KRYS $153.22
  • KAI $357.98
  • Analyst Decision
  • KRYS Strong Buy
  • KAI Buy
  • Analyst Count
  • KRYS 11
  • KAI 2
  • Target Price
  • KRYS $204.27
  • KAI $327.50
  • AVG Volume (30 Days)
  • KRYS 273.0K
  • KAI 105.7K
  • Earning Date
  • KRYS 08-04-2025
  • KAI 07-29-2025
  • Dividend Yield
  • KRYS N/A
  • KAI 0.38%
  • EPS Growth
  • KRYS 109.01
  • KAI N/A
  • EPS
  • KRYS 4.16
  • KAI 8.98
  • Revenue
  • KRYS $333,448,000.00
  • KAI $1,024,121,000.00
  • Revenue This Year
  • KRYS $40.10
  • KAI N/A
  • Revenue Next Year
  • KRYS $49.73
  • KAI $4.52
  • P/E Ratio
  • KRYS $36.72
  • KAI $39.86
  • Revenue Growth
  • KRYS 247.53
  • KAI 1.74
  • 52 Week Low
  • KRYS $122.80
  • KAI $281.30
  • 52 Week High
  • KRYS $212.06
  • KAI $429.95
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 60.29
  • KAI 67.07
  • Support Level
  • KRYS $147.35
  • KAI $340.35
  • Resistance Level
  • KRYS $154.99
  • KAI $343.86
  • Average True Range (ATR)
  • KRYS 4.27
  • KAI 9.68
  • MACD
  • KRYS 0.11
  • KAI 2.21
  • Stochastic Oscillator
  • KRYS 69.85
  • KAI 78.42

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About KAI Kadant Inc

Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.

Share on Social Networks: